TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to observe the effect of TACE/HAIC combined with lenvatinib and
sintilimab as a neoadjuvant therapy before liver resection in preventing the recurrence in
high-risk patients with hepatocellular carcinoma.